Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of three injectable drugs, indicating progress in its oncology pipeline [1] Group 1: Clinical Trial Approvals - The company's subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Medicine Co., Ltd., have been granted clinical trial approval for SHR-1826, Adebali monoclonal antibody injection, and Bevacizumab injection [1] - SHR-1826 is an antibody-drug conjugate targeting c-MET, designed to selectively bind to tumor cell surface antigens and induce cell death [1] - Adebali monoclonal antibody injection, a humanized anti-PD-L1 monoclonal antibody, aims to block the PD-1/PD-L1 pathway, reactivating the immune system's anti-tumor activity [1] Group 2: Product Development and Market Status - Adebali monoclonal antibody injection (brand name: Ailili) was approved for market in March 2023 for first-line treatment of extensive-stage small cell lung cancer in combination with carboplatin and etoposide [1] - Bevacizumab, a humanized anti-VEGF monoclonal antibody, was co-developed by domestic and foreign pharmaceutical companies and has been marketed since 2004 in the U.S. under the brand name Avastin [1] - The company's Bevacizumab injection was approved for market in June 2021, with multiple formulations currently available in China and globally [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of three injectable drugs, indicating progress in its oncology pipeline [1] Group 1: Drug Approvals - The company's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., and Shanghai Shengdi Pharmaceutical Co., Ltd. have received clinical trial approval for SHR-1826, Adebali monoclonal antibody injection, and Bevacizumab injection [1] - SHR-1826 is an antibody-drug conjugate targeting c-MET, designed to selectively bind to tumor cell surface antigens and induce cell death [1] - Adebali monoclonal antibody injection, a humanized anti-PD-L1 monoclonal antibody, aims to block the PD-1/PD-L1 pathway, reactivating the immune system's anti-tumor activity [1] - Adebali monoclonal antibody injection (brand name: Ailili) was approved for market in March 2023 for first-line treatment of extensive-stage small cell lung cancer in combination with carboplatin and etoposide [1] - Bevacizumab is a humanized anti-VEGF monoclonal antibody, co-developed by Genentech and a Chinese pharmaceutical company, and has been marketed globally since its approval in the U.S. in 2004 [1] - The company's Bevacizumab injection was approved for market in June 2021, with multiple formulations currently available in China [1]

Core Viewpoint - Heng Rui Medicine (600276) has announced a 2025 A-share employee stock ownership plan aimed at establishing a profit-sharing mechanism among the company, shareholders, and employees to enhance employee motivation, creativity, cohesion, and overall competitiveness, thereby promoting the company's long-term and sustainable development [1] Summary by Relevant Sections - The employee stock ownership plan involves the repurchase of up to 14 million A-shares, accounting for approximately 0.21% of the company's total share capital as of the announcement date [1] - The repurchase price is set at 30.95 yuan per share, with the final number of shares held under the plan to be determined based on actual execution [1] - The total number of employees participating in the plan is expected to be no more than 1,316 (excluding reserved shares), with a maximum of 9 individuals from the board (excluding independent directors), supervisors, and senior management [1]

Core Viewpoint - Heng Rui Medicine (01276) has announced a 2025 A-share employee stock ownership plan aimed at establishing a profit-sharing mechanism among the company, shareholders, and employees to enhance employee motivation, creativity, cohesion, and overall company competitiveness, promoting long-term and sustainable development [1] Summary by Relevant Sections - Employee Stock Ownership Plan Details - The plan involves the acquisition of up to 14 million A-shares (including reserved shares), accounting for approximately 0.21% of the company's total share capital as of the announcement date [1] - The acquisition price is set at 30.95 yuan per share, with the final number of shares held under the plan to be determined based on actual execution [1] - Participation and Eligibility - The total number of employees participating in the plan is expected to be no more than 1,316 (excluding reserved shares) [1] - Among the participants, the number of company directors (excluding independent directors), supervisors, and senior management is limited to no more than 9 (excluding reserved shares), with the final number of participants and subscription details to be confirmed based on actual employee contributions [1]

Core Insights - The innovative drug HRS-1893 has achieved a significant breakthrough with a licensing agreement between Heng Rui Medicine and Braveheart Bio, with a potential total transaction value of nearly 8 billion RMB [1][5] - The collaboration highlights the international recognition of China's innovative drug research and the focus on Southeast University's organ-on-a-chip technology [1][5] Group 1: Drug Development and Mechanism - HRS-1893 is designed to treat obstructive hypertrophic cardiomyopathy and functions as a selective inhibitor of cardiac myosin [3] - The drug's development involved collaboration with Professor Gu Zhongze's team at Southeast University, utilizing organ-on-a-chip technology for cell activity screening [3][7] Group 2: Clinical Trials and Licensing Agreement - HRS-1893 received approval for clinical trials in May 2023, marking it as the first new drug in China to use organ-on-a-chip data for such approval [5] - Braveheart Bio will have exclusive rights to develop, produce, and commercialize HRS-1893 globally, excluding certain regions in China, with Heng Rui Medicine set to receive an upfront payment of $7.5 million and potential milestone payments totaling up to $1.013 billion [5][8] Group 3: Technological Advancements and Future Plans - The organ-on-a-chip team at Southeast University has made significant advancements in key technologies over the past decade, achieving breakthroughs in high-precision 3D printing and functional biomaterials [7] - Future plans include further technological innovation and collaboration with more pharmaceutical companies to create new pathways for drug development and precision medicine [8]

证券简称：恒瑞医药 证券代码：600276 江苏恒瑞医药股份有限公司 2025 年 A 股员工持股计划 2025 年 9 月 声明 本公司及全体董事保证本员工持股计划及其摘要不存在虚假记载、误导性陈 述或重大遗漏，并对其真实性、准确性、完整性承担个别和连带的法律责任。 1 特别提示 本部分内容中的词语简称与"释义"部分保持一致。 1、《江苏恒瑞医药股份有限公司 2025 年 A 股员工持股计划》系江苏恒瑞医 药股份有限公司依据《中华人民共和国公司法》《中华人民共和国证券法》《关 于上市公司实施员工持股计划试点的指导意见》《上海证券交易所上市公司自律 监管指引第 1 号——规范运作》等法律、行政法规、规章、规范性文件以及《江 苏恒瑞医药股份有限公司章程》的有关规定制定。 2、本员工持股计划遵循依法合规、自愿参与、风险自担的原则，不存在摊 派、强行分配等强制员工参加本员工持股计划的情形。 3、本员工持股计划的参加对象为公司董事（不含独立董事）、监事、高级 管理人员、公司及控股子公司核心管理人员、骨干员工和公司董事会认为应当激 励的其他员工。本员工持股计划的参加对象总人数不超过 1316 人（不含预留份 额），其中 ...

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-144 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司苏州盛迪亚 生物医药有限公司、上海盛迪医药有限公司收到国家药品监督管理局（以下简称 "国家药监局"）核准签发关于注射用 SHR-1826、阿得贝利单抗注射液、贝伐 珠单抗注射液的《药物临床试验批准通知书》，将于近期开展临床试验。现将相 关情况公告如下： 野生型的晚期/转移性非鳞状非小细胞肺癌成人患者。截至目前，注射用 SHR-1826 相关项目累计研发投入约 8,809 万元。 阿得贝利单抗注射液是公司自主研发的人源化抗 PD-L1 单克隆抗体，能通过 特异性结合 PD-L1 分子从而阻断导致肿瘤免疫耐受的 PD-1/PD-L1 通路，重新激 活免疫系统的抗肿瘤活性，从而达到治疗肿瘤的目的。公司阿得贝利单抗注射液 （商品名：艾瑞利）已于 2023 年 3 月获批上市，获批的适应症为与卡铂 ...

Core Points - The Medical Health R Index (480016) closed at 8278.77 points, down 0.33%, with a trading volume of 31.765 billion yuan and a turnover rate of 1.08% [1] - Among the index constituents, 18 stocks rose while 31 fell, with Yirui Technology leading the gainers at a 4.4% increase and Zexin Pharmaceutical leading the decliners at a 5.37% decrease [1] Index Constituents Summary - The top ten constituents of the Medical Health R Index include: - WuXi AppTec (sh603259) with a weight of 13.58% and a market cap of 315.96 billion yuan [1] - Hengrui Medicine (sh600276) with a weight of 10.87% and a market cap of 458.96 billion yuan [1] - Mindray Medical (sz300760) with a weight of 8.17% and a market cap of 290.50 billion yuan [1] - United Imaging Healthcare (sh688271) with a weight of 4.14% and a market cap of 126.08 billion yuan [1] - Other notable constituents include Pianzai Shou (sh600436), Yierfu Technology (sz300015), Kelun Pharmaceutical (sz002422), New Hope Liuhe (sz002001), Fosun Pharma (sh600196), and East China Pharmaceutical (sz000963) [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 1.638 billion yuan, while retail investors saw a net inflow of 1.098 billion yuan [1] - Notable capital flows include: - Kailai Ying (002821) with a main fund net inflow of 101 million yuan [2] - Mindray Medical (300760) with a main fund net inflow of approximately 90.77 million yuan [2] - Yuyue Medical (002223) with a main fund net inflow of 24.60 million yuan [2]

本次会议是否有否决议案：无 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-143 一、 会议召开和出席情况 江苏恒瑞医药股份有限公司 2025年第一次临时股东会决议公告 (一)股东会召开的时间：2025 年 9 月 16 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 1、出席会议的股东和代理人人数 | 4,505 | | --- | --- | | 股股东人数 其中：A | 4,504 | | 境外上市外资股股东人数（H 股） | 1 | | 2、出席会议的股东所持有表决权的股份总数（股） | 3,068,160,282 | | 其中：A 股股东持有股份总数 | 2,900,683,191 | | 境外上市外资股股东持有股份总数（H 股） | 167,477,091 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 46.2869 | | 其中：A 股股东持股占股份总数的比例（%） | 43.7603 | | 境外上市外资股股东持股 ...

www.grandall.com.cn 中国江苏省南京市汉中门大街 309 号 B 座 5、7-8 层（210036） 5、7-8F/Block B, 309# Hanzhongmen Street, Nanjing, China Tel: 86-25-89660900 Fax: 86-25-89660966 国浩律师（南京）事务所 关于 江苏恒瑞医药股份有限公司 2025 年第一次临时股东会的 法律意见书 致：江苏恒瑞医药股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下 简称"《股东会规则》"）、《上海证券交易所上市公司自律监管指引第 1 号— —规范运作》(以下简称"《监管指引第 1 号》")及《江苏恒瑞医药股份有限公 司章程》（以下简称"《公司章程》"）的规定，国浩律师（南京）事务所（以 下简称"本所"）接受江苏恒瑞医药股份有限公司（以下简称"公司"）的委托， 指派刘向明律师、张秋子律师（以下简称"本所律师"）出席公司 2025 年第一次 临时股东会（以下简称"本次股东会"或"本次会议"），对本次股东 ...